Albemarle — Aug 5, 2026 release

Operations at the Jordan Bromine Company (JBC) joint venture are in line with expectations as it continues to navigate geopolitical tensions in the region. Segment FY 2026E Specialties net sales $1.4 - $1.6 billion Specialties adjusted EBITDA $275 - $325 million Other Corporate Outlook Considerations Albemarle expects its full-year 2026 capital expenditures to be approximately $500 million, down 15% compared to 2025 due to ongoing capital efficiency improvements. Following the sale of a controlling stake in Ketjen’s refining catalyst solutions business, announced on March 2, 2026, the refining catalyst business earnings are now classified as equity income and included in Corporate, as are the results of the retained Performance Catalyst Solutions (PCS) business. The adjusted EBITDA and equity income contributions from these are expected to be immaterial post transaction. Interest and financing expense is expected to be between $120 and $140 million for 2026 following the debt reduction actions completed in the first quarter of 2026. Other Corporate FY 2026E Capital expenditures ~$500 million Depreciation and amortization $660 - $680 million Adjusted effective tax rate (a) (50)% - 30% Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS) ($20) - $20 million Interest and financing expenses $120 - $140 million Weighted-average common shares outstanding (diluted) (b) ~136 million (a)    Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b)    Diluted weighted-average common shares outstanding amount assumes the conversio